Ionis Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Ionis Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ionis Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ionis Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals Inc, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases, including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy, Waylivra for familial chylomicronemia syndrome, Qalsody for superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), and Wainua for polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US
Headquarters
United States of America
Address
2855 Gazelle Court, Carlsbad, California, 92010
Website
www.ionis.com
Telephone
1 760 9319200
No of Employees
1,402
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IONS (NASD)
Revenue (2024)
$943.7M
33.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
16%
(2024 vs 2023)
Market Cap*
$9.2B
Net Profit Margin (2024)
XYZ
37.2%
(2024 vs 2023)
* As of and is in US$
Ionis Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nusinersen - Spinal Muscular Atrophy | Spinraza |
| Inotersen - Polyneuropathy | Tegsedi |
| Volanesorsen - Familial Chylomicronemia Syndrome | Waylivra |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received a grant from the U.S. Food and Drug Administration to olezarsen as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). |
| 2025 | Regulatory Approval | In December, the company received breakthrough therapy designation from the U.S. Food and Drug Administration for zilganersen for the treatment of Alexander disease. |
| 2025 | Regulatory Approval | In September, the company and Sobi secured approval of Tryngolza (olezarsen) in the European Union (EU) for adults with familial chylomicronemia syndrome. |
Competitor Comparison
| Key Parameters | Ionis Pharmaceuticals Inc | Eli Lilly and Co | Pfizer Inc | AstraZeneca Plc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | Switzerland |
| City | Carlsbad | Indianapolis | New York City | Cambridge | Basel |
| State/Province | California | Indiana | New York | Cambridgeshire | Basel-Stadt |
| No. of Employees | 1,402 | 50,605 | 75,000 | 96,100 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joseph Loscalzo, M.D., Ph.D. | Chairman | Executive Board | 2014 | 74 |
| Brett P. Monia, Ph.D. | Chief Executive Officer; Director | Executive Board | 2020 | 64 |
| Elizabeth L. Hougen | Chief Financial Officer; Executive Vice President - Finance | Senior Management | 2020 | 64 |
| Darren Gonzales | Chief Accounting Officer; Senior Vice President | Senior Management | 2020 | - |
| Patrick R. O’Neil | Chief Legal Officer; Secretary; Executive Vice President; General Counsel | Senior Management | 2021 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer